You are here
- Home
- Therapy Areas
- Cardiovascular
A long term open label study to evaluate the safety and efficacy of dapagliflozin as monotherapy or combination therapies with anti-diabetic drugs in Japanese subjects with type 2 diabetes who have inadequate glycemic control
- Disease
- diabetes type 2
- Drug Name
- dapagliflozin
- Sponsor
- AstraZeneca
- Drug Status
- Approved Medicine
- Phase
- III
- Start Date
- Feb 28, 2011
- Study Name
- D1692C00012
- Study Id
- D1692C00012
- ClinicalTrials.gov ID
- NCT01294436
- Recruiting Status
- Closed
- Protocol Status
- Not Available
- Report Status
- Not Available
